April 29, 2019
A Washington, D.C.-based consumer advocacy group asked a federal court on Monday to force the U.S. Food and Drug Administration to act on its 2016 petition saying dopamine agonist drugs should have a black-box warning about side effects that can cause compulsive behavior.